|

PULSed Field Ablation for Atrial Fibrillation Using a Balloon for Early Intervention - Study

RECRUITINGN/ASponsored by Asklepios proresearch
Actively Recruiting
PhaseN/A
SponsorAsklepios proresearch
Started2026-08-19
Est. completion2030-03-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07621003

Summary

This study is a prospective, multicenter, randomized, open-label, blinded end-point, controlled clinical trial to investigate the impact of first line pulsed field ablation during 12 months follow-up in patients with early-stage paroxysmal or persistent atrial fibrillation (\<3 years) compared to usual care, defined as OMT.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults (≥18 years) with symptomatic or asymptomatic, paroxysmal or persistent atrial fibrillation
* First diagnosis of AF within the last 36 months
* At least one documented episode of AF on ECG, Holter monitoring, or eligible Smart Watch Device
* No prior catheter ablation for AF

Exclusion Criteria:

* Persistent AF \>3 years or longstanding persistent AF
* Previous AF-Ablation
* Ongoing continuous AAD therapy with Amiodarone at baseline
* History of failed continuous AAD therapy with \> 1 agent. Exceptions are Beta blocker, Verapamil or "pill in the pocket"-therapy
* Left Atrial Volume Index (LAVI) \> 50mL/m2
* Severe mitral regurgitation
* Contraindications to anticoagulation therapy
* Severe pulmonary or renal disease
* Pregnancy, active cancer disease
* Any condition or disease which is contraindication for AF ablation within 21 days or Anti-Arrhythmic Drug (AAD)

Conditions2

Atrial FibrillationHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.